simenepag isopropyl
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2009 (NCT00809848)
Timeline
Indications
Mechanism of action
- Prostanoid EP2 receptorAGONIST
PTGER2 agonist
Chemistry & pharmacology
Loading structure…
SMILES
CCCCC[C@H](O)c1ccc(N2C(=O)CC[C@@H]2COCc2ccc(C(=O)OC(C)C)s2)cc1- Mol. weight
- 473.64 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2105710 ↗
Also known as
- agn-210669
- agn-210669
- agn-210669
- simenepag isopropyl
- simenepag isopropyl
- simenepag isopropyl
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01291108 | Phase 2 | Apr 1, 2011 | Allergan |
| NCT01001195 | Phase 2 | Nov 1, 2009 | Allergan |
| NCT00809848 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2009 | Allergan |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Allergan | For profit | 3 | 3 | 1 | 2009 |
1 organizations
Page 1 / 1